

2.04.136 Nutrient/Nutritional Panel Testing	
Original Policy Date: January 1, 2016	Effective Date: February 1, 2024
Section: 2.0 Medicine	Page: Page 1 of 10

Policy Statement

- I. Nutrient/nutritional panel testing is considered **investigational** for all indications including but not limited to testing for nutritional deficiencies in individuals with mood disorders, fibromyalgia, or unexplained fatigue, and healthy individuals.

NOTE: Refer to [Appendix A](#) to see the policy statement changes (if any) from the previous version.

Policy Guidelines

- N/A

Description

Multimarker nutritional panel testing is proposed for patients with certain chronic conditions (e.g., mood disorders, fibromyalgia, unexplained fatigue) as well as for healthy individuals seeking to optimize health and/or fitness.

Related Policies

- Cardiovascular Risk Panels

Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

Regulatory Status

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Nutrient/nutritional panel testing using urine and/or blood samples is offered (e.g., NutrEval FMV[®] and NutrEval Plasma[®] by Genova Diagnostics; micronutrient testing by SpectraCell) under the auspices of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

An independent member of the Blue Shield Association

Rationale

Background

Nutritional panel testing aims to identify nutritional deficiencies that will lead to personalized nutritional supplement recommendations. Testing is proposed both for healthy individuals to optimize health and for patients with chronic conditions (e.g., mood disorders, fibromyalgia, unexplained fatigue) to specify supplements that will ameliorate symptoms.

Genova Diagnostics offers nutritional/nutrient panel testing. Among the tests this company offers is NutrEval® FMV, which involves analysis of urine and blood samples and provides information on more than 100 markers including organic acids, amino acids, fatty acids, markers of oxidative stress (direct measurement of glutathione and CoQ10, and markers of oxidative injury and DNA damage) and nutrient elements (Table 1).¹ Genova Diagnostics produces a report that includes test results categorized as minimal, moderate, or high need for support, along with recommendations for supplements and dosages for items categorized as high need. NutrEval FMV patient reports can recommend supplementation for any of the nutrients listed in Table 1 if they are found to be areas of high need.

NutrEval Plasma, also by Genova Diagnostics, is a similar test.² The only difference between NutrEval FMV and NutrEval Plasma is that the former uses urine (first morning void) whereas the latter uses plasma (fasting sample) to measure amino acids.

SpectraCell Laboratories offers a micronutrient test that measures functional deficiencies at the cellular level.³ The test assesses how well the body uses 31 vitamins, minerals, amino and fatty acids, antioxidants, and metabolites (see Table 1). SpectraCell categorizes test results into adequate, borderline, and deficient, and offers supplementation suggestions based on each patient's deficiencies.

Table 1. Components of the NutrEval FMV and Spectra Cell Tests

Category	NutrEval FMV	Spectra Cell Nutrient Testing
Vitamins and antioxidants	Vitamin A, vitamin C, vitamin E, alpha-lipoic acid, coenzyme Q10, glutathione, plant-based antioxidants, B vitamins (thiamin B ₁ , riboflavin B ₂ , niacin B ₃ , pyridoxine B ₆ , biotin B ₇ , folic acid B ₉ , cobalamin B ₁₂)	Vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₃ , vitamin B ₆ , vitamin B ₁₂ , biotin, folate, pantothenate, vitamin C, vitamin D, vitamin K, alpha-lipoic acid, coenzyme Q10, cysteine, glutathione, selenium, vitamin E
Minerals	Magnesium, manganese, molybdenum, zinc	Calcium, magnesium, manganese, zinc, copper
Fatty acids	Omega-3-oils	
Digestive support	Probiotics, pancreatic enzymes	
Other vitamins	Vitamin D	
Amino acids	Arginine, asparagine, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, taurine, threonine, tryptophan, tyrosine, valine	Asparagine, glutamine, serine
Metabolites		Choline, inositol, carnitine

Literature Review

Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical

reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

Nutrient/Nutritional Panel Testing Clinical Context and Test Purpose

The purpose of nutrient/nutritional panel testing in individuals who have mood disorders, fibromyalgia, or unexplained fatigue or in healthy individuals seeking to optimize health and fitness is to inform a decision on whether the patient might benefit from specific nutrient supplementation. The following PICO was used to select literature to inform this review.

Populations

The relevant populations of interest are individuals with mood disorders, fibromyalgia, or unexplained fatigue, or healthy individuals seeking to optimize health and fitness.

Interventions

The relevant intervention of interest is nutrient/nutritional panel testing.

Comparators

The following practice is currently being used to manage mood disorders, fibromyalgia, unexplained fatigue, or healthy individuals seeking to optimize health and fitness: standard of care.

Outcomes

The potential beneficial outcomes of primary interest are an improvement in symptoms, change in disease status, and functional outcomes. The potential harmful outcomes are those resulting from a false test result. False-positive or false-negative test results can lead to the initiation of unnecessary treatment and adverse events from overtreatment or undertreatment.

Nutrient/nutritional panel testing might be conducted before or after starting specific therapy for the specific conditions addressed herein or as a screening test for healthy individuals seeking to optimize health and fitness.

Study Selection Criteria

For the evaluation of clinical validity of the nutrient/nutritional panel testing, studies that meet the following eligibility criteria were considered:

- Reported on the accuracy of the marketed version of the technology (including any algorithms used to calculate scores).
- Included a suitable reference standard.
- Patient/sample clinical characteristics were described.
- Patient/sample selection criteria were described.

Clinically Valid

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

No studies on the sensitivity and specificity of nutrient/nutritional panel testing compared with a reference standard were identified.

Clinically Useful

A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence

Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs).

No RCTs were identified that assessed the clinical utility of nutrient/nutritional panel testing for mood disorders, fibromyalgia, unexplained fatigue, or optimization of health and fitness.

Chain of Evidence

Indirect evidence on clinical utility rests on clinical validity. If the evidence is insufficient to demonstrate test performance, no inferences can be made about clinical utility.

The chain of evidence to support the clinical utility of the use of nutrient/nutritional panel testing would consist of: (1) evidence that specific nutritional deficiencies included in the panel test are significantly associated with mood disorders, fibromyalgia, and/or unexplained fatigue; (2) evidence that, in patients with mood disorders, fibromyalgia, and/or unexplained fatigue, treatment of a patient found to have specific nutritional deficiencies (e.g., with nutritional supplements) improves health outcomes; and (3) evidence that, if there is sufficient evidence on the first 2 items, panel testing is more appropriate than testing for specific nutrients.

Association of Mood Disorders, Fibromyalgia, or Unexplained Fatigue with Nutritional Deficiencies

Systematic Reviews

Several systematic reviews and meta-analyses evaluating associations between the indications of interest (depression, fibromyalgia) and specific nutrient deficiencies were identified, and they are described in Table 2. No systematic reviews or meta-analyses were identified in the association between nutritional deficiencies and unexplained fatigue. A limitation of all reviews is that, although they compared low and high levels of nutrient levels, none addressed whether these low levels constituted actual deficiencies in a particular nutrient.

Table 2. Systematic Reviews on the Association Between Nutritional Deficiencies and Mood Disorders, Fibromyalgia, and/or Unexplained Fatigue

Study	Nutrient	No. of Studies	Specified Cutoff for Nutrient Deficiency	Key Findings (95% CI)
Depression				
Petridou et al (2015) ⁴	Folate and vitamin B ₁₂	11	No	Odds of having depression significantly associated with low folate and vitamin B levels: <ul style="list-style-type: none"> Folate: OR, 1.27 (1.07 to 1.43) Vitamin B: OR, 1.20 (1.02 to 1.42)
Cheungpasitporn et al (2015) ⁵	Magnesium	6	No	Pooled RR of depression in patients with hypomagnesemia (3 cohort studies, 2 cross-sectional studies, 1 case-control study combined; N=19,137 patients): <ul style="list-style-type: none"> 1.34 (1.01 to 1.79; <i>P</i>=33%) Pooled RR excluding the cross-sectional studies:

Study	Nutrient	No. of Studies	Specified Cutoff for Nutrient Deficiency	Key Findings (95% CI)
Swardfager et al (2013) ⁶	Zinc	17	No	<ul style="list-style-type: none"> 1.38 (0.92 to 2.07; $P=24\%$) Mean serum zinc concentrations of $-1.85 \mu\text{mol/L}$ (-2.52 to $-1.19 \mu\text{mol/L}$) in depressed patients vs. nondepressed controls ($p<.001$)
Anglin et al (2013) ⁷	Vitamin D	14	No	Cross-sectional studies: <ul style="list-style-type: none"> OR of depression, highest vs. lowest vitamin D categories: 1.31 (1.00 to 1.71; $p=.03$) Prospective series: <ul style="list-style-type: none"> Risk of depression significantly higher in patients with lower vitamin D (HR=2.21; 1.40 to 3.49; $p=.028$)
Fibromyalgia				
Hsiao et al (2015) ⁸	Vitamin D	12	No	Significantly higher odds of hypovitaminosis D among patients with chronic pain including fibromyalgia vs. control group: <ul style="list-style-type: none"> Crude OR, 1.63 (1.20 to 2.23) Adjusted OR, 1.41 (1.00 to 2.00)
Daniel and Pitotta (2011) ⁹	Vitamin D		No	No pooled analyses. Lower-quality studies tended to find positive associations between fibromyalgia and low vitamin D levels; studies with control groups found no significant associations; larger population-based studies had mixed findings

CI: confidence interval; HR: hazard ratio; OR: odds ratio; RR: relative risk.

Subsection Summary: Association of Mood Disorders, Fibromyalgia, or Unexplained Fatigue with Nutritional Deficiencies

Evidence from multiple systematic reviews and meta-analyses of observational studies have indicated an association between deficiency of nutrients (vitamin B₁₂, vitamin D, folate, magnesium, zinc) and different outcomes (depression, fibromyalgia). There is no evidence whether screening for these nutrient deficiencies results in improved health outcomes compared with no screening.

Treatment of Mood Disorders, Fibromyalgia, or Unexplained Fatigue in Patients with Nutritional Deficiencies

Systematic Reviews

Two systematic reviews evaluating health outcomes in patients with depression treated with nutritional supplementation were identified, and they are described in Table 3. A limitation of these reviews is that they did not require patients to have an established deficiency of any nutrient. No systematic reviews or meta-analyses were identified on nutritional interventions in patients with fibromyalgia or unexplained fatigue.

Table 3. Systematic Reviews on Interventions for Patients with Mood Disorders, Fibromyalgia, and/or Unexplained Fatigue Diagnosed with Nutritional Deficiencies

Study	Intervention and Comparator	No. and Type of Studies	Patients Diagnosed With Nutritional Deficiencies	Key Findings (95% CI)
Depression				
Gowda et al (2015) ¹⁰	Vitamin D (alone or combined with other vitamins or	9 RCTs	<ul style="list-style-type: none"> No in overall analysis 	<ul style="list-style-type: none"> No significant difference found in depression after supplementation

Study	Intervention and Comparator	No. and Type of Studies	Patients Diagnosed With Nutritional Deficiencies	Key Findings (95% CI)
	antidepressants) vs. placebo		<ul style="list-style-type: none"> • Yes in subgroup analysis 	<ul style="list-style-type: none"> • with vitamin D vs. placebo (SMD=0.28; -0.14 to 0.69) • No significant difference found in depression with vitamin D vs. placebo in patients with baseline vitamin D >50 nmol/L or in patients with baseline vitamin D <50 nmol/L
Taylor et al (2003)¹¹	Folic acid (alone or as adjunctive treatment) vs. antidepressant medication	3 RCTs	No	<ul style="list-style-type: none"> • Difference in HDRS scores significantly lower in patients taking folic acid plus antidepressants vs. antidepressants alone (MD=-2.65; -4.93 to -0.038)

CI: confidence interval; HDRS: Hamilton Depression Rating Scale; MD: mean difference; RCT: randomized controlled trial; SMD: standard mean difference.

Randomized Controlled Trials

Nowak et al (2016) conducted a single-center, double-blind, placebo-controlled trial to determine whether a single vitamin D dose would reduce fatigue after 30 days among 120 otherwise healthy persons with low serum 25-hydroxyvitamin D levels (mean age, 29 years; 53% women).¹² The outcome was measured using the Fatigue Assessment Scale. The vitamin D group had a significantly greater decrease in mean (standard deviation) Fatigue Assessment Scale score (-3.3, standard deviation=5.3) than the placebo group (-0.8, standard deviation=5.3; $p=.01$). Improvements were reported more frequently in the vitamin D group (42 [72%]) than in placebo group (31 [50%]; $p=.01$; odds ratio, 2.63; 95% confidence interval for odds ratio, 1.23 to 5.62). Among all participants, improvement in the Fatigue Assessment Scale correlated with the rise in 25-hydroxyvitamin D levels ($r=0.22$, $p=.02$).

Subsection Summary: Treatment of Mood Disorders, Fibromyalgia, or Unexplained Fatigue in Patients with Nutritional Deficiencies

A systematic review of RCTs has suggested that folate might have a role as a supplement to other therapies in patients with depression. However, it is unclear whether folate supplementation would benefit both people with normal folate levels and those with folate deficiency. A meta-analysis of RCTs has suggested no significant benefit of vitamin D supplementation versus placebo in the case of depression. An RCT reported decreased fatigue in patients receiving a single dose of vitamin D, and suggested improvements in fatigue with vitamin D supplementation. There is no evidence whether screening for these nutrient deficiencies (versus no screening) would result in significant improvement in outcomes.

Panel Testing versus Testing for Individual Nutrients

There is no evidence on any indication to suggest that nutritional panel testing improves the net health outcome compared with testing for 1 or several individual nutrients. This applies to patients with mood disorders, fibromyalgia, and/or unexplained fatigue, as well as healthy individuals seeking to optimize health and/or fitness. Moreover, with nutritional panel testing, there is a potential for incidental findings that could cause harm. Examples of potential harms include unnecessary confirmatory tests, unnecessary treatments provided for clinically insignificant conditions, toxicity related to supplementation, and interactions between nutritional supplements and prescription medications.

Supplemental Information

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest. No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

The U.S. Preventive Services Task Force (USPSTF) has not addressed nutritional panel testing. The USPSTF has made several recommendations addressing screening for individual nutrients. The USPSTF concluded that there is insufficient evidence to recommend for or against screening for iron deficiency anemia in asymptomatic children, adolescents and pregnant women, as well as vitamin D deficiency in asymptomatic, nonpregnant adults.^{13,14,15}

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

A search of ClinicalTrials.gov in October 2023 did not identify any ongoing or unpublished trials that would likely influence this review.

References

1. Genova Diagnostics. NutrEval FMV; <https://www.gdx.net/product/nutreval-fmv-nutritional-test-blood-urine>. Accessed October 20, 2023.
2. Genova Diagnostics. NutrEval Plasma; <https://www.gdx.net/product/nutreval-nutritional-test-plasma>. Accessed October 21, 2023.
3. SpectraCell Laboratories Micronutrient Test Panel. <https://spectracell.sitewrench.com/search-tests>. Accessed October 21, 2023.
4. Petridou ET, Kousoulis AA, Michelakos T, et al. Folate and B12 serum levels in association with depression in the aged: a systematic review and meta-analysis. *Aging Ment Health*. Sep 2016; 20(9): 965-73. PMID 26055921
5. Cheungpasitporn W, Thongprayoon C, Mao MA, et al. Hypomagnesaemia linked to depression: a systematic review and meta-analysis. *Intern Med J*. Apr 2015; 45(4): 436-40. PMID 25827510
6. Swardfager W, Herrmann N, Mazereeuw G, et al. Zinc in depression: a meta-analysis. *Biol Psychiatry*. Dec 15 2013; 74(12): 872-8. PMID 23806573
7. Anglin RE, Samaan Z, Walter SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br J Psychiatry*. Feb 2013; 202: 100-7. PMID 23377209
8. Hsiao MY, Hung CY, Chang KV, et al. Is Serum Hypovitaminosis D Associated with Chronic Widespread Pain Including Fibromyalgia? A Meta-analysis of Observational Studies. *Pain Physician*. 2015; 18(5): E877-87. PMID 26431141
9. Daniel D, Pirotta MV. Fibromyalgia--should we be testing and treating for vitamin D deficiency?. *Aust Fam Physician*. Sep 2011; 40(9): 712-6. PMID 21894281
10. Gowda U, Mutowo MP, Smith BJ, et al. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. *Nutrition*. Mar 2015; 31(3): 421-9. PMID 25701329
11. Taylor MJ, Carney S, Geddes J, et al. Folate for depressive disorders. *Cochrane Database Syst Rev*. 2003; 2003(2): CD003390. PMID 12804463
12. Nowak A, Boesch L, Andres E, et al. Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial. *Medicine (Baltimore)*. Dec 2016; 95(52): e5353. PMID 28033244

13. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia in Pregnant Women: Screening and Supplementation. 2015.
<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-pregnant-women-screening-and-supplementation>. Accessed October 19, 2023.
14. U.S. Preventive Services Task Force (USPSTF). Iron Deficiency Anemia: Screening. 2015;
<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/iron-deficiency-anemia-in-young-children-screening#fullrecommendationstart>. Accessed October 20, 2023.
15. U.S. Preventive Services Task Force (USPSTF). Vitamin D Deficiency: Screening. 2021;
<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-deficiency-screening>. Accessed October 21, 2023.

Documentation for Clinical Review

- No records required

Coding

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy.

The following codes are included below for informational purposes. Inclusion or exclusion of a code(s) does not constitute or imply member coverage or provider reimbursement policy. Policy Statements are intended to provide member coverage information and may include the use of some codes for clarity. The Policy Guidelines section may also provide additional information for how to interpret the Policy Statements and to provide coding guidance in some cases.

Type	Code	Description
CPT®	82128	Amino acids; multiple, qualitative, each specimen
	82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
	82746	Folic acid; serum
	83735	Magnesium
	83785	Manganese
	84590	Vitamin A
	84630	Zinc
HCPCS	None	

Policy History

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

Effective Date	Action
01/01/2016	BCBSA Medical Policy Adoption
03/01/2016	Administrative Update (Correction to Documentation for Clinical Review section)
06/01/2017	Policy revision without position change
02/01/2018	Policy revision without position change
02/01/2019	Policy revision without position change
03/01/2020	Annual review. No change to policy statement. Literature review updated.
02/01/2024	Policy reactivated. Previously archived from 03/01/2020 to 1/31/2024.

Definitions of Decision Determinations

Medically Necessary: Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member's illness, injury, or disease.

Investigational/Experimental: A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

Split Evaluation: Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.

Prior Authorization Requirements and Feedback (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

We are interested in receiving feedback relative to developing, adopting, and reviewing criteria for medical policy. Any licensed practitioner who is contracted with Blue Shield of California or Blue Shield of California Promise Health Plan is welcome to provide comments, suggestions, or concerns. Our internal policy committees will receive and take your comments into consideration.

For utilization and medical policy feedback, please send comments to: MedPolicy@blueshieldca.com

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.

Appendix A

POLICY STATEMENT	
BEFORE	AFTER
<p>Reactivated Policy</p> <p>Policy Statement: N/A</p>	<p>Nutrient/Nutritional Panel Testing 2.04.136</p> <p>Policy Statement:</p> <ol style="list-style-type: none"> I. Nutrient/nutritional panel testing is considered investigational for all indications including but not limited to testing for nutritional deficiencies in individuals with mood disorders, fibromyalgia, or unexplained fatigue, and healthy individuals.